Events and Presentations

Date

Title

Supporting Materials

ISTH – Marzeptacog alfa (activated) population pharmacokinetics (PK): Simulations for dose selection in Phase 3 trials 2.1 MB

ISTH – Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of ascending doses of subcutaneous marzeptacog alfa (activated) in adult subjects with hemophilia 1 MB

Supporting Materials

WFH - Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene Therapy 2 MB

Supporting Materials

Raymond James Human Health Innovation Conference Presentation 2.6 MB

Supporting Materials

Phase 2b Trial to Evaluate the Safety and Factor IX Levels of a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacog alfa in Hemophilia B 2.1 MB

Supporting Materials

Cowen Healthcare Conference Presentation 2.2 MB

Supporting Materials

Phase 2b Trial to Evaluate the Safety & Factor IX Levels Resulting from a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacog Alfa in Haemophilia B 528.7 KB

Supporting Materials

Phase 2b Trial to Evaluate the Safety & Factor IX Levels Resulting from a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacog Alfa in Haemophilia B 528.7 KB

Investor Presentation 2.2 MB

Supporting Materials

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports On-Demand Treatment in Hemophilia A Mice 1.8 MB

Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of ascending doses of subcutaneous marzeptacog alfa (activated) in adult subjects with hemophilia 519.2 KB

Hemophilia B Gene Therapy in Mice Using a Novel Chimeric AAV Capsid Combined With the Potency Enhanced CB 2679d-GT FIX Variant 1.4 MB

Supporting Materials

Catalyst Biosciences at the ASBMB Conference Presentation 12.2 MB

Supporting Materials

KOL event for analysts and investors on MarzAA, next-generation Factor VIIa Marzeptacog alfa (activated) in individuals with bleeding disorders Presentation 15.3 MB

Supporting Materials

Phase 2/3 Trial of Subcutaneous Engineered FVIIa Marzeptacog Alfa (Activated) in Hemophilia A or B with Inhibitors: Efficacy, Safety and Pharmacokinetics 394.8 KB

Quality of Life of Hemophilia Patients with Inhibitors – Opportunities for Improvement 709 KB

Phase 2 Trial of Subcutaneous Engineered FIX Dalcinonacog alfa: Pharmacokinetics and Safety 422.7 KB

A Comprehensive In Silico And In Vitro Immunogenicity Risk Assessment of Dalcinonacog Alfa Shows No Increased Risk Compared With Wild-type FIX 1.8 MB

Supporting Materials

CB 2782-PEG: a Complement Factor C3-Inactivating Protease and Potential Long- Acting Treatment for Dry AMD 1.6 MB

Supporting Materials

Phase 2/3 trial of subcutaneous engineered FVIIa marzeptacog alfa (activated) in hemophilia A or B with inhibitors: Pharmacokinetics, pharmacodynamics, efficacy and safety 6.8 MB

Quality of Life For Haemophilia Patients with Inhibitors 591.7 KB

AAV Based Hemophilia B Gene Therapy in Mice Using FIX-CB2679d-GT 462.7 KB

Supporting Materials

Catalyst Biosciences Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs 4.9 MB

Supporting Materials

Phase 1/2 Trial of Single and Multiple Dose Subcutaneously Administered Factor Ix Variant Cb2679d/Isu304: Pharmacokinetics and Safety 1.3 MB

Phase 2/3 Trial of Subcutaneously Administered Novel Fviia Variant Marzeptacog Alfa (Activated) In Hemophilia A or B with Inhibitors: Pharmacokinetics, Pharmacodynamics, Safety and Efficacy 2.7 MB

Home
Contact